Results 71 to 80 of about 49,427 (236)

DP133 | CIP2A IS IMPLICATED IN RUXOLITINIB RESISTANCE IN MYELOFIBROSIS

Haematologica
Although ruxolitinib (Ruxo) is the standard of care for patients (pts) with myelofibrosis (MF), therapeutic resistance develops in approximately 50% within 3-5 years, posing a clinical challenge.
M. Balliu, M. Vannucchi, M.C. Siciliano, M. Lomi, C. Basile, P. Guglielmelli, A.M. Vannucchi   +6 more
doaj  

Philadelphia-negative chronic myeloproliferative neoplasms

Revista Brasileira de Hematologia e Hemoterapia, 2012
Chronic myeloproliferative diseases without the Philadelphia chromosome marker (Ph-), although first described 60 years ago, only became the subject of interest after the turn of the millennium.
Rosane Isabel Bittencourt, Jose Vassallo, Maria de Lourdes Lopes Ferrari Chauffaille, Sandra Guerra Xavier, Katia Borgia Pagnano, Ana Clara Kneese Nascimento, Carmino Antonio De Souza, Carlos Sergio Chiattone   +7 more
doaj   +1 more source

Rare Causes of Acute Coronary Syndrome: The JAK2 V617F Mutation-Positive Myeloproliferative Neoplasms: A Cardio-Hematological Perspective [PDF]

, 2022
Silvia Cantoni, Claudia Colombo, Francesco Soriano, Jacopo Oreglia, Alice Sacco, Silvio Veronese, Dario Brunelli, Andrea Rubboli, Nuccia Morici   +8 more
openalex   +1 more source

P211 | NEUTROPHIL-TO-LYMPHOCYTES RATIOS CAN PREDICT OUTCOMES AND TREATMENT RESPONSE IN MYELOFIBROSIS PATIENTS: A SINGLE-CENTER RETROSPECTIVE STUDY

Haematologica
Background: Myelofibrosis (MF) is the most symptomatic form of MPN and carries the worst outcome. Neutrophil-to-lymphocyte ratio (NLR), platelet-to-lymphocyte ratio (PLR), systemic immune-inflammation index (SII) and systemic inflammation response index
G. Capecchi, V. Boldrini, G. Coltro, G. G. Loscocco, L. Fagiolo, G. Borgi, C. Matteoli, T. Barbui, A.M. Vannucchi, P. Guglielmelli   +9 more
doaj  

Low Dose Splenic Radiotherapy for Myeloproliferative Neoplasms prior to Allogeneic Hematopoietic Stem Cell Transplant [PDF]

, 2023
Claire Baniel, Laura Johnston, Christopher Jackson, Sally Arai, Susan M. Hiniker, Richard T. Hoppe, Michael S. Binkley   +6 more
openalex   +1 more source

Age, JAK2V617F and SF3B1 mutations are the main predicting factors for survival in refractory anaemia with ring sideroblasts and marked thrombocytosis [PDF]

, 2013
Broséus, J., Alpermann, T., Wulfert, M., Florensa Brichs, L., Jeromin, S., Lippert, E., Rozman, M., Lifermann, F., Grossmann, V., Haferlach, T., Germing, U., Luño, E., Girodon, F., Schnittger ...
Alpermann, T., Brichs, L. F., Broséus, Julien, Grossmann, V., Jeromin, S., Lifermann, F., Lippert, E., Luño Fernández, Elisa, Rozman, M., Wulfert, M.   +9 more
core   +1 more source

JAK2V617F-bearing vascular niche enhances malignant hematopoietic regeneration following radiation injury

Haematologica, 2018
Myeloproliferative neoplasms are clonal stem cell disorders characterized by hematopoietic stem/progenitor cell expansion. The acquired kinase mutation JAK2V617F plays a central role in these disorders.
Chi Hua Sarah Lin, Yu Zhang, Kenneth Kaushansky, Huichun Zhan   +3 more
doaj   +1 more source

Improved Diagnosis of the Transition to JAK2V617F Homozygosity: The Key Feature for Predicting the Evolution of Myeloproliferative Neoplasms [PDF]

, 2013
Most cases of BCR-ABL1-negative myeloproliferative neoplasms (MPNs), essential thrombocythemia, polycythemia vera and primary myelofibrosis are associated with JAK2V617F mutations.
Bianchini, Michele, de Brasi, Carlos Daniel, Gargallo, Patricia Martha, Gonzalez, Mariana Selena, Larripa, Irene Beatriz, Stanganelli, Carmen Graciela, Zalcberg, Ilana   +6 more
core   +3 more sources

C019 | INIBITION OF PI3KΔ BY ROGINOLISIB (IOA-244) AS A POTENTIAL THERAPEUTIC STRATEGY FOR MYELOFIBROSIS

Haematologica
Due to its clonal stem cell origins and the resulting dysregulation of the JAK/STAT pathway, myelofibrosis (MF) treatment has undergone a paradigm shift with the development of JAK-inhibitors.
M. Balliu, G. Di Conza, M. Lahn, P. Guglielmelli, A.M. Vannucchi   +4 more
doaj  

DNA Methylation in Ph-Negative Myeloproliferative Neoplasms: Prognostic Role and Therapeutic Implications

Current Issues in Molecular Biology
Myeloproliferative neoplasms are clonal hematological neoplasms characterized by excessive proliferation of cells of erythroid, granulocytic, and megakaryocytic lineage.
Paola Barone, Adele Bottaro, Rossana Leanza, Fabio Stagno, Alessandro Allegra   +4 more
doaj   +1 more source